Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Spillane

Showing results (191-200 of 223) with videos related to

Pageof 23
Sort By:
Australian Journal of General Practice|May 29, 2020
Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma managementCaroline G Watts, Andrea L Smith, Sam Robinson, et al.
The Lancet. Oncology|June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trialGeorgina V Long, Robyn P M Saw, Serigne Lo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanomaM T Tetzlaff, C Adhikari, S Lo, et al.
Human Molecular Genetics|July 28, 2020
Multiplex melanoma families are enriched for polygenic riskMatthew H Law, Lauren G Aoude, David L Duffy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA CalculatorAlexander H R Varey, Isabel Li, Mary-Ann El Sharouni, et al.
Annals of Surgical Oncology|November 15, 2023
Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional ImagingCaroline A Gjorup, Rachel Woodford, Isabel Li, et al.
JAMA Surgery|February 9, 2022
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III MelanomaIrene L M Reijers, Robert V Rawson, Andrew J Colebatch, et al.
NPJ Breast Cancer|October 29, 2025
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trialsShelley Potter, Kerry Avery, Rosina Ahmed, et al.
International Journal of Cancer|September 5, 2018
Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibilityJames S Wilmott, Peter A Johansson, Felicity Newell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.
Pageof 23

Showing results (191-200 of 223) with videos related to

Sort By:
Pageof 23
Australian Journal of General Practice|May 29, 2020
Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma managementCaroline G Watts, Andrea L Smith, Sam Robinson, et al.
The Lancet. Oncology|June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trialGeorgina V Long, Robyn P M Saw, Serigne Lo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanomaM T Tetzlaff, C Adhikari, S Lo, et al.
Human Molecular Genetics|July 28, 2020
Multiplex melanoma families are enriched for polygenic riskMatthew H Law, Lauren G Aoude, David L Duffy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA CalculatorAlexander H R Varey, Isabel Li, Mary-Ann El Sharouni, et al.
Annals of Surgical Oncology|November 15, 2023
Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional ImagingCaroline A Gjorup, Rachel Woodford, Isabel Li, et al.
JAMA Surgery|February 9, 2022
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III MelanomaIrene L M Reijers, Robert V Rawson, Andrew J Colebatch, et al.
NPJ Breast Cancer|October 29, 2025
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trialsShelley Potter, Kerry Avery, Rosina Ahmed, et al.
International Journal of Cancer|September 5, 2018
Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibilityJames S Wilmott, Peter A Johansson, Felicity Newell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.
Pageof 23